Mandating Exclusive Review of Individual Treatments (MERIT) Act

Bill: 117-hr-9127
Sponsor: full_name: Rep. Buchanan, Vern [R-FL-16]
Introduced: 2022-10-04
Policy area: Health
Subjects: Medical research

Medicare

Prescription drugs
Latest action: action_date: 2022-10-05
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2022-10-04
action_desc: Introduced in House
text: <p><b>Mandating Exclusive Review of Individual Treatments (MERIT) Act</b></p> <p>This bill specifies that coverage determinations for drugs and biologics under Medicare must be made with respect to each drug or biologic, rather than with respect to a class of drugs or biologics.</p>

tv_txt: I 117th CONGRESS 2d Session H. R. 9127 IN THE HOUSE OF REPRESENTATIVES October 4, 2022 Mr. Buchanan (for himself and Ms. Barragán ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XVIII of the Social Security Act to clarify the use of the national coverage determination process under the Medicare program.

1. Short title This Act may be cited as the Mandating Exclusive Review of Individual Treatments (MERIT) Act . 2. Clarification on Medicare national coverage determination process Section 1862(a) of the Social Security Act ( 42 U.S.C. 1395y(a) ) is amended by adding at the end the following new sentence: For purposes of paragraph (1)(E), in the case of research conducted pursuant to section 1142, the determination of whether a drug or biological is reasonable and necessary to carry out the purposes of section 1142 shall be made with respect to each drug or biological involved and not with respect to a class of drugs or biologicals. .